Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duration of Surfactant Administration in Very Preterm Neonates: 1 Minute vs 5 Minutes
2025-522754-39-00Phase 4Authorised
- Sponsor
- Medical University of Graz
- Start
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Poractant alfa in respiratory distress syndrome (RDS) (2 arms), sponsored by Medical University of Graz. Planned start Dec 2025; status: authorised.
02
Drugs
Poractant alfa
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on 2025-522754-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522754-39-00.